Item 4.01 Changes in Registrant’s Certifying Accountant.
(a) Dismissal of Previous Independent Registered Public Accounting Firm
On June 12, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Coherus Oncology, Inc. (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm, with dismissal effective as of such date.
The reports of EY on the consolidated financial statements of the Company as of and for the fiscal years ended December 31, 2025 and 2024 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.
During the Company’s fiscal years ended December 31, 2025 and 2024 and the subsequent interim period through June 12, 2026: (1) there were no “disagreements” (as defined in Item 304(a)(1)(iv) of Regulation S-K) with EY on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of EY, would have caused EY to make reference to the subject matter of such disagreements in connection with its reports on the consolidated financial statements for such periods and (2) there were no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K), except that, as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 17, 2025, the Company reported a material weakness in its internal control over financial reporting during such period related to documentation and review of certain inventory account reconciliations. As reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 9, 2026, management concluded that the material weakness had been remediated and its internal control over financial reporting was effective.
The Company provided EY with a copy of this Current Report on Form 8-K and requested that EY furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether EY agrees with the statements made herein. A copy of the letter from EY is filed with this Current Report on Form 8-K as Exhibit 16.1.
(b) Appointment of New Independent Registered Public Accounting Firm
On June 12, 2026, the Audit Committee of the Board of Directors of the Company selected PricewaterhouseCoopers LLP (“PwC”) to be appointed to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, subject to standard client acceptance procedures. During the fiscal years ended December 31, 2025 and 2024, and the subsequent interim period through June 12, 2026, the Company did not consult with PwC regarding any of the matters described in Items 304(a)(2)(i) and (ii) of Regulation S-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| | |
Exhibit No. | | Description |
16.1 | | Letter from Ernst & Young LLP to the Securities and Exchange Commission dated June 15, 2026 |
| | |
| | |
104 | | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| | |
